By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating in Philadelphia, Pennsylvania, by NewsRx journalists, research stated, "G protein coupled receptor kinase 2 (GRK2) plays a central role in the regulation of a variety of important signaling pathways. Alternation of GRK2 protein level and activity casts profound effects on cell physiological functions and causes diseases such as heart failure, rheumatoid arthritis, and obesity."
The news reporters obtained a quote from the research from Thomas Jefferson University, "We have previously reported that overexpression of GRK2 has an inhibitory role in cancer cell growth. To further examine the role of GRK2 in cancer, in this study, we investigated the effects of reduced protein level of GRK2 on insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in human hepatocellular carcinoma (HCC) HepG2 cells. We created a GRK2 knockdown cell line using a lentiviral vector mediated expression of GRK2 specific short hairpin RNA (shRNA). Under IGF-1 stimulation, HepG2 cells with reduced level of GRK2 showed elevated total IGF-1R protein expression as well as tyrosine phosphorylation of receptor. In addition, HepG2 cells with reduced level of GRK2 also demonstrated increased tyrosine phosphorylation of IRS1 at the residue 612 and increased phosphorylation of Akt, indicating a stronger activation of IGF-1R signaling pathway. However, HepG2 cells with reduced level of GRK2 did not display any growth advantage in culture as compared with the scramble control cells. We further detected that reduced level of GRK2 induced a small cell cycle arrest at G2/M phase by enhancing the expression of cyclin A, B1, and E."
According to the news reporters, the research concluded: "Our results indicate that GRK2 has contrasting roles on HepG2 cell growth by negatively regulating the IGF-1R signaling pathway and cyclins' expression."
For more information on this research see: GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells. Journal of Cellular Physiology, 2013;228(9):1897-901. (Wiley-Blackwell - www.wiley.com/; Journal of Cellular Physiology - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4652)
Our news correspondents report that additional information may be obtained by contacting Z. Wei, Division of Transplantation, Dept. of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, United States. Additional authors for this research include R. Hurtt, T. Gu, A.S. Bodzin, W.J. Koch and C. Doria (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Philadelphia, Pennsylvania, United States, Cancer Gene Therapy, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC